Get the Stockscreener App
7.08
1.12%
-0.08
Kamada Ltd stock is traded at $7.08, with a volume of 118.05K.
It is down -1.12% in the last 24 hours and up +20.00% over the past month.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
See More
Previous Close:
$7.16
Open:
$7.16
24h Volume:
118.05K
Relative Volume:
1.62
Market Cap:
$407.05M
Revenue:
$154.57M
Net Income/Loss:
$15.07M
P/E Ratio:
26.22
EPS:
0.27
Net Cash Flow:
$10.92M
1W Performance:
-1.80%
1M Performance:
+20.00%
6M Performance:
+22.49%
1Y Performance:
+20.61%
1-Day Range:
$6.90
$7.1624
1-Week Range:
$6.90
$7.35
52-Week Range:
$4.74
$8.00
Kamada Ltd Stock (KMDA) Company Profile
Compare KMDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
7.08 | 407.05M | 154.57M | 15.07M | 10.92M | 0.27 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-03-24 | Initiated | Stifel | Buy |
| Feb-02-18 | Initiated | Chardan Capital Markets | Buy |
Kamada Ltd Stock (KMDA) Latest News
Kamada Ltd. (NASDAQ:KMDA) Short Interest Up 33.3% in December - MarketBeat
Kamada’s (KMDA) Buy Rating Reiterated at HC Wainwright - Defense World
Market Participants Recognise Kamada Ltd.'s (TLV:KMDA) Earnings Pushing Shares 25% Higher - Simply Wall St
Kamada's (KMDA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Kamada Projects Double-Digit Growth for 2025, Expands Plasma Operations - Yahoo Finance
Kamada Affirms 2024 Financial Guidance and Announces Expected Continued Double-Digit Profitable Growth for 2025 - GlobeNewswire
Kamada Projects Strong 2025 Growth: 13% Revenue Jump to $182M, EBITDA to Rise 19% - StockTitan
KMDA stock touches 52-week high at $6.53 amid market optimism By Investing.com - Investing.com South Africa
Kamada (NASDAQ:KMDA) Stock Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
Comparing Endonovo Therapeutics (OTCMKTS:ENDVD) & Kamada (NASDAQ:KMDA) - Defense World
KMDA stock touches 52-week high at $6.53 amid market optimism - Investing.com Australia
Financial Survey: Kamada (NASDAQ:KMDA) versus Endonovo Therapeutics (OTCMKTS:ENDVD) - Defense World
Exploring High Growth Tech Stocks This January 2025 - Yahoo Finance
Kamada Ltd. (NASDAQ:KMDA) Short Interest Update - MarketBeat
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 - The Manila Times
Exploring Undiscovered Gems with Potential This December 2024 - Simply Wall St
So who replaces Eberechi Eze against Arsenal? Crystal Palace boss asked if summer signing will step in - South London News
Music Industry Moves: Avex USA Names Ryusuke Kamada CFO - Yahoo Entertainment
Kamada Ltd. Approves Board Re-Elections and Auditor Appointment - TipRanks
Gauzy Appoints Lilach Payorski to Board - Glass Magazine
Gauzy Adds to Board of Directors - CleanLink
Here's Why Shareholders May Want To Be Cautious With Increasing Kamada Ltd.'s (TLV:KMDA) CEO Pay Packet - Simply Wall St
Short Interest in Kamada Ltd. (NASDAQ:KMDA) Expands By 8.9% - Defense World
Gauzy Appoints Seasoned Public Company Executive and Director Lilach Payorski to Board of Directors - The Manila Times
Gauzy Strengthens Board with Ex-Stratasys CFO Lilach Payorski as Audit Chair | GAUZ Stock News - StockTitan
Maxkamada Banaadir oo soo saartay Waaran lagu soo xirayo Madaxweynaha Jubaland - Horseed Media
Solid Earnings Reflect Kamada's (TLV:KMDA) Strength As A Business - Simply Wall St
Alpha 1 Antitrypsin Deficiency Treatment Market Analysis By Top - openPR
HC Wainwright Issues Pessimistic Outlook for Kamada Earnings - MarketBeat
What is HC Wainwright’s Forecast for Kamada FY2024 Earnings? - Defense World
Alpha-1 Antitrypsin Deficiency Therapy Market 2024-2031 - openPR
HC Wainwright Forecasts Kamada's Q4 Earnings (NASDAQ:KMDA) - MarketBeat
Earnings call: Kamada Ltd. reports growth and raises EBITDA outlook - Investing.com India
Phoenix Financial Ltd. Increases Stake in Kamada Ltd. - GuruFocus.com
Kamada Ltd. (NASDAQ:KMDA) Q3 2024 Earnings Call Transcript - Insider Monkey
Kamada Ltd (KMDA) Q3 2024 Earnings Call Highlights: Strong Reven - GuruFocus.com
Kamada Ltd (KMDA) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Increased EBITDA ... - Yahoo Finance
Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market to Grow - openPR
Alpha-1 Antitrypsin Deficiency Market Expected to Experience Major Growth by 2034, According to DelveInsight | Kamada Pharma, Mereo BioPharma/AstraZeneca, Grifols Therapeutics LLC, Takeda, Vertex - Barchart
Earnings call: Kamada Ltd. reports growth and raises EBITDA outlook By Investing.com - Investing.com Australia
Kamada: Q3 Earnings Snapshot - Barchart
Kamada reports Q3 EPS 7c, consensus 7c - TipRanks
Kamada’s Strong Growth and Strategic Expansion in 2024 - TipRanks
KMDAKamada Ltd Latest Stock News & Market Updates - StockTitan
Kamada Reports Continued Profitable Growth with Strong Third Quarter and Nine Month 2024 Financial Results; Raises Full-Year Profitability Guidance - The Manila Times
Kamada Reports Continued Profitable Growth with Strong - GlobeNewswire
Kamada Q3 Revenue Surges 10% to $41.7M, Boosts EBITDA Guidance Amid Strong Growth | KMDA Stock News - StockTitan
How Oliver Glasner can get the best out of Daichi Kamada after terrible start - We Are Palace
Report shares who was actually responsible for bringing Daichi Kamada to Crystal Palace - We Are Palace
Kamada Ltd Stock (KMDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):